| Glypican-3–specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma SA Batra, P Rathi, L Guo, AN Courtney, J Fleurence, J Balzeau, RS Shaik, ... Cancer immunology research 8 (3), 309-320, 2020 | 190 | 2020 |
| Redirecting T cells to glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity W Li, L Guo, P Rathi, E Marinova, X Gao, MF Wu, H Liu, G Dotti, ... Human gene therapy 28 (5), 437-448, 2017 | 107 | 2017 |
| Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results A Heczey, X Xu, AN Courtney, G Tian, GA Barragan, L Guo, CM Amador, ... Nature Medicine 29 (6), 1379-1388, 2023 | 61 | 2023 |
| A phase I clinical trial using armored GPC3 CAR T cells for children with relapsed/refractory liver tumors. DHM Steffin, SA Batra, P Rathi, L Guo, W Li, AN Courtney, LS Metelitsa, ... Journal of Clinical Oncology 37 (15_suppl), TPS2647-TPS2647, 2019 | 10 | 2019 |
| Glypican-3-specific CAR-NKT cells overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma. RS Shaik, P Rathi, A Courtney, N Schneller, L Guo, G Barragan, C Zhang, ... Journal of Clinical Oncology 40 (16_suppl), e14521-e14521, 2022 | 2 | 2022 |
| Anti-GD2 CAR NKT cells are safe and produce antitumor responses in patients with relapsed/refractory neuroblastoma A Heczey, A Courtney, N Ghatwai, S Thakkar, P Rathi, X Xu, H Ngai, ... Mol Ther 30 (4 suppl 1), 28, 2022 | 2 | 2022 |
| Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers D Steffin, N Ghatwai, A Montalbano, P Rathi, AN Courtney, AB Arnett, ... Research Square, 2024 | 1 | 2024 |
| A phase 1 clinical trial using armored GPC3-car T cells for children with relapsed/refractory liver tumors DHM Steffin, N Ghatwai, S Batra, JJ Fleurence, P Rathi, AN Courtney, ... MOLECULAR THERAPY 28 (4), 212-213, 2020 | 1 | 2020 |
| Armored Glypican-3-Specific CAR T Cells for the Immunotherapy of Hepatocellular Carcinoma SA Batra, P Rathi, W Li, T Nguyen, AN Courtney, N Schneller, ... MOLECULAR THERAPY 26 (5), 441-441, 2018 | 1 | 2018 |
| Glypican-3-Specific CAR NKT Cells Armored with IL-15 Exhibit Potent and Sustained Anti-Tumor Activity against Hepatocellular Carcinoma T Nguyen, P Rathi, S Batra, A Courtney, L Metelitsa, A Heczey MOLECULAR THERAPY 26 (5), 62-62, 2018 | 1 | 2018 |
| Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results A Heczey, X Xu, AN Courtney, G Tian, GA Barragan, L Guo, CM Amador, ... Nature medicine 30 (4), 1210, 2024 | | 2024 |
| GD2-CAR NKTS CAN INDUCE ANTITUMOR RESPONSES IN CHILDREN WITH NEUROBLASTOMA (NB) AND BTG1 REPRESSION CAN FURTHER BOOST THEIR THERAPEUTIC POTENTIAL IN NB MODELS AA Heczey, X Xu, AN Courtney, G Tian, GA Barragan, L Guo, CM Amador, ... PEDIATRIC BLOOD & CANCER 71, S8-S8, 2024 | | 2024 |
| INTERLEUKIN-15 CO-EXPRESSION INDUCES ROBUST EXPANSION AND ANTITUMOR EFFECT OF GPC3-CAR T CELLS AND TOXICITIES CAN BE MITIGATED WITH THE INDUCIBLE CASPASE-9 SAFETY SWITCH D Steffin, N Ghatwai, C Zhang, P Rathi, A Courtney, B Grilley, L Metelitsa, ... PEDIATRIC BLOOD & CANCER 69, S330-S331, 2022 | | 2022 |
| Interleukin-15 Co-Expression Induces Robust in vivo Expansion and Antitumor Effect of Glypican-3-Specific CAR T Cells in a Patient with Liver Cancer D Steffin, N Ghatwai, C Zhang, P Rathi, A Courtney, R Sweidan, P Lulla, ... MOLECULAR THERAPY 30 (4), 371-371, 2022 | | 2022 |
| Car t cells with one or more interleukins A Heczey, S Batra, P Rathi US Patent App. 17/050,341, 2021 | | 2021 |
| Glypican-3-Specific CAR NKT Cells Armored with IL-15 Mediate Potent Anti-Tumor Response Against Hepatocellular Carcinoma R Shaik, P Rathi, N Schneller, T Nguyen, L Guo, A Courtney, J Fleurence, ... MOLECULAR THERAPY 28 (4), 34-35, 2020 | | 2020 |
| Armored GPC3 CAR T Cells for Children with Relapsed/Refractory Liver Tumors S Batra, D Steffin, P Rathi, L Guo, W Li, A Courtney, L Metelitsa, A Heczey PEDIATRIC BLOOD & CANCER 66, 2019 | | 2019 |
| Glypican-3-specific CAR-NKTs overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma P Rathi, R Shaik, A Courtney | | |
